These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1581 related items for PubMed ID: 8564971

  • 1. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F.
    Cancer Res; 1996 Feb 01; 56(3):556-62. PubMed ID: 8564971
    [Abstract] [Full Text] [Related]

  • 2. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection.
    Righetti SC, Perego P, Corna E, Pierotti MA, Zunino F.
    Cell Growth Differ; 1999 Jul 01; 10(7):473-8. PubMed ID: 10437915
    [Abstract] [Full Text] [Related]

  • 3. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
    Kolfschoten GM, Hulscher TM, Schrier SM, van Houten VM, Pinedo HM, Boven E.
    Gynecol Oncol; 2002 Mar 01; 84(3):404-12. PubMed ID: 11855878
    [Abstract] [Full Text] [Related]

  • 4. Normal p53 status and function despite the development of drug resistance in human breast cancer cells.
    Wosikowski K, Regis JT, Robey RW, Alvarez M, Buters JT, Gudas JM, Bates SE.
    Cell Growth Differ; 1995 Nov 01; 6(11):1395-403. PubMed ID: 8562478
    [Abstract] [Full Text] [Related]

  • 5. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS, Mills GB, Khokhar AR, Bast RC, Siddik ZH.
    Clin Cancer Res; 1999 Mar 01; 5(3):655-63. PubMed ID: 10100719
    [Abstract] [Full Text] [Related]

  • 6. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2.
    Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young LS.
    Oncogene; 1995 Oct 05; 11(7):1217-28. PubMed ID: 7478541
    [Abstract] [Full Text] [Related]

  • 7. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line.
    Siddik ZH, Mims B, Lozano G, Thai G.
    Cancer Res; 1998 Feb 15; 58(4):698-703. PubMed ID: 9485023
    [Abstract] [Full Text] [Related]

  • 8. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
    Song K, Li Z, Seth P, Cowan KH, Sinha BK.
    Oncol Res; 1997 Feb 15; 9(11-12):603-9. PubMed ID: 9563008
    [Abstract] [Full Text] [Related]

  • 9. Induction of apoptosis by the p53-273L (Arg --> Leu) mutant in HSC3 cells without transactivation of p21Waf1/Cip1/Sdi1 and bax.
    Kaneuchi M, Yamashita T, Shindoh M, Segawa K, Takahashi S, Furuta I, Fujimoto S, Fujinaga K.
    Mol Carcinog; 1999 Sep 15; 26(1):44-52. PubMed ID: 10487521
    [Abstract] [Full Text] [Related]

  • 10. Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST1926, an atypical retinoid.
    Zuco V, Zanchi C, Cassinelli G, Lanzi C, Supino R, Pisano C, Zanier R, Giordano V, Garattini E, Zunino F.
    Cell Death Differ; 2004 Mar 15; 11(3):280-9. PubMed ID: 14657960
    [Abstract] [Full Text] [Related]

  • 11. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
    Kern MA, Helmbach H, Artuc M, Karmann D, Jurgovsky K, Schadendorf D.
    Anticancer Res; 1997 Mar 15; 17(6D):4359-70. PubMed ID: 9494534
    [Abstract] [Full Text] [Related]

  • 12. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
    Goldwasser F, Bae I, Fornace AJ, Pommier Y.
    Oncol Res; 1996 Mar 15; 8(7-8):317-23. PubMed ID: 8938795
    [Abstract] [Full Text] [Related]

  • 13. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.
    Caserini C, Pratesi G, Tortoreto M, Bedogné B, Carenini N, Supino R, Perego P, Righetti SC, Zunino F.
    Clin Cancer Res; 1997 Jun 15; 3(6):955-61. PubMed ID: 9815771
    [Abstract] [Full Text] [Related]

  • 14. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53.
    Jones NA, Turner J, McIlwrath AJ, Brown R, Dive C.
    Mol Pharmacol; 1998 May 15; 53(5):819-26. PubMed ID: 9584207
    [Abstract] [Full Text] [Related]

  • 15. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
    Henkels KM, Turchi JJ.
    Cancer Res; 1999 Jul 01; 59(13):3077-83. PubMed ID: 10397248
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53.
    Ramirez PT, Gershenson DM, Tortolero-Luna G, Ramondetta LM, Fightmaster D, Wharton JT, Wolf JK.
    Gynecol Oncol; 2001 Dec 01; 83(3):543-8. PubMed ID: 11733969
    [Abstract] [Full Text] [Related]

  • 18. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel.
    Debernardis D, Siré EG, De Feudis P, Vikhanskaya F, Valenti M, Russo P, Parodi S, D'Incalci M, Broggini M.
    Cancer Res; 1997 Mar 01; 57(5):870-4. PubMed ID: 9041188
    [Abstract] [Full Text] [Related]

  • 19. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells.
    Chang FL, Ling YF, Lai MD.
    Anticancer Res; 2000 Mar 01; 20(1A):329-36. PubMed ID: 10769676
    [Abstract] [Full Text] [Related]

  • 20. TNF-alpha induced p21(WAF1) but not Bax in colon cancer cells WiDr with mutated p53: important role of protein stabilization.
    Kobayashi N, Takada Y, Hachiya M, Ando K, Nakajima N, Akashi M.
    Cytokine; 2000 Dec 01; 12(12):1745-54. PubMed ID: 11097743
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 80.